返回管委会首页
繁體 |English |日语 |无障碍 |关怀版
Home page > Category Report > Industries & Enterprises

Chinese and Japanese elites from biomedical and financial sectors dialogue online

Date:2022-04-21 10:37:58|Source:|Font Size: AAA

The Dialogue on Innovation in Biomedicine, one of the Jinji Lake Sino-Japanese Cooperation and Exchange series jointly sponsored by SIP Investment Promotion Committee (SIPIPC), China Medicine Advance Committee and Suzhou Sino-Japanese Medicine and New Material Innovation Center, was held online on Apr 14, gathering more than 200 Chinese and Japanese elites from the biomedical and financial sectors.

http://www.sipac.gov.cn/szgyyq/jsdt/202204/62b6d74148d54ccdbd4bd92cc3171ff1/images/966c638046b647f9b92c6be0c199a262.jpg

At the event, the representative from SIPIPC gave the participants a detailed introduction to SIP’s efforts and achievements in bolstering the biomedical industry and facilitating cooperation between Chinese and Japanese partners in this sector.

It is learnt that there are about 800 Japanese-invested projects in SIP currently, including 45 invested by 26 Fortune 500 enterprises from Japan. SIP has enhanced efforts in recent years to build platforms and host such events as innovation and entrepreneurship competitions and forums to attract Japanese investors and help Chinese companies to enter the Japanese market.

In the event, Wang Di, business development director from EPS International, Xu Ping, chairman of Huili Pharma, and executives from Takeda, Daiichi Sankyo, TF Securities, Long Hill Capital, EVERSANA and other companies and organizations shared their insights on prospects of the biomedical industry and cooperation opportunities from different perspectives.

April 19, 2022

Copyright © www.sipac.gov.cn   |  Contact us